Restructuring, Impairment and Related Charges (Tables)

6 Months Ended

Sep. 30, 2020

Restructuring and Related Activities [Abstract]

Restructuring, Impairment and Related Costs

Restructuring, impairment, and related charges during the three and six months ended September 30, 2020 consisted of the following:

	Three Months Ended September 30, 2020
(In millions)	U.S. Pharmaceutical		International (1)		Medical-Surgical Solutions		Prescription Technology Solutions		Corporate (2)		Total
Severance and employee-related costs, net	$	6	$	3	$	3	$	—	$	4	$	16
Exit and other-related costs (3)	4		5		(1)		—		7		15
Asset impairments and accelerated depreciation	—		27		1		—		1		29
Total	$	10	$	35	$	3	$	—	$	12	$	60

(1)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(2)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above.

(3)Exit and other-related costs primarily consist of project consulting fees.

	Six Months Ended September 30, 2020
(In millions)	U.S. Pharmaceutical		International (1)		Medical-Surgical Solutions		Prescription Technology Solutions		Corporate (2)		Total
Severance and employee-related costs, net	$	7	$	20	$	3	$	—	$	24	$	54
Exit and other-related costs (3)	5		7		2		—		14		28
Asset impairments and accelerated depreciation	—		31		1		—		2		34
Total	$	12	$	58	$	6	$	—	$	40	$	116

(1)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(2)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above.

(3)Exit and other-related costs primarily consist of project consulting fees.

Fiscal 2020

Restructuring, impairment, and related charges during the three and six months ended September 30, 2019 consisted of the following:

	Three Months Ended September 30, 2019
(In millions)	U.S. Pharmaceutical (1)		International (2)		Medical-Surgical Solutions (3)		Prescription Technology Solutions		Corporate (4)		Total
Severance and employee-related costs, net	$	3	$	5	$	1	$	—	$	10	$	19
Exit and other-related costs (5)	—		4		2		—		13		19
Asset impairments and accelerated depreciation	—		3		—		—		4		7
Total	$	3	$	12	$	3	$	—	$	27	$	45

(1)Primarily represents costs associated with the relocation of the Company’s corporate headquarters described above.

(2)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(3)Primarily represents costs associated with a growth initiative which included a reduction in workforce, facility consolidation, and store closures. These initiatives were substantially completed in the year ended March 31, 2020.

(4)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above.

(5)Exit and other-related costs primarily include project consulting fees.

	Six Months Ended September 30, 2019
(In millions)	U.S. Pharmaceutical (1)		International (2)		Medical-Surgical Solutions (3)		Prescription Technology Solutions		Corporate (4)		Total
Severance and employee-related costs, net	$	2	$	4	$	1	$	—	$	16	$	23
Exit and other-related costs (5)	—		6		4		—		23		33
Asset impairments and accelerated depreciation	—		6		1		—		5		12
Total	$	2	$	16	$	6	$	—	$	44	$	68

(1)Primarily represents costs associated with the relocation of the Company’s corporate headquarters described above.

(2)Primarily represents costs associated with the operating model and cost optimization efforts described above.

(3)Primarily represents costs associated with a growth initiative which included a reduction in workforce, facility consolidation, and store closures. These initiatives were substantially completed in the year ended March 31, 2020.

(4)Represents costs associated with the operating model cost optimization efforts and with the relocation of the Company’s corporate headquarters described above.

(5)Exit and other-related costs primarily include project consulting fees.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the six months ended September 30, 2020:

(In millions)	U.S. Pharmaceutical		International		Medical-Surgical Solutions		Prescription Technology Solutions		Corporate		Total
Balance, March 31, 2020 (1)	$	29	$	66	$	22	$	1	$	39	$	157
Restructuring, impairment, and related charges	12		58		6		—		40		116
Non-cash charges	—		(31)		(1)		—		(2)		(34)
Cash payments	(15)		(16)		(11)		(1)		(34)		(77)
Other	—		(1)		(1)		—		(5)		(7)
Balance, September 30, 2020 (2)	$	26	$	76	$	15	$	—	$	38	$	155

(1)As of March 31, 2020, the total reserve balance was $157 million, of which $118 million was recorded in Other accrued liabilities and $39 million was recorded in Other non-current liabilities.

(2)As of September 30, 2020, the total reserve balance was $155 million, of which $128 million was recorded in Other accrued liabilities and $27 million was recorded in Other non-current liabilities.